TMPRSS2-ERG fusion gene in a cohort of chinese prostatectomy patients and its relevence with clinicopathologic characters and prognosis for endocrine therapy

Jing Tao,Haojie Zhang,Li Xiao,Lu Sheng,Weiqing Qian,Zhongquan Sun

DOI: https://doi.org/10.3969/j.issn.1008-0848.2016.12.003

2016-01-01

Abstract:Objective To investigate the prevalence of TMPRSS2-ERG gene fusion in Chinese prostate cancer and its correlation with clinicopathologic parameters, as well as its prognostic significance for patients with endocrine therapy.Methods Total of 96 needle biopsy samples of patients with prostate cancers were collected from October, 2010 to December, 2014, and their clinical data was collected. All patients received endocrine therapy and were followed up. Fluorescence in situ hybridization (FISH) was used to detect TMPRSS2-ERG gene fusion in these specimens.Results TMPRSS2-ERG gene fusion accounted for 19.8% (19 cases), deletion pattern 57.9% (11cases) and translocation pattern 57.9% (11). 3(15.8%) had both deletion and insertion pattern. There were no significant differences between fusion positive and negative cases in the distribution of age (0.348), PSA(0.525), Gleason score(0.348), primary Gleason pattern (0.52), T stage (0.856) and metastasis (0.622). Similarly, no difference was observed between fusion positive and negative cases in progression free time (PFS) of these patients.Conclusion The prevalence of TMPRRSS2-ERG gene fusion is significantly lower in Chinese population than the western countries. TMRPSS2-ERG gene fusion is not correlated with age, PSA, Gleason score, primary Gleason pattern and TNM stage. It has no prognostic value for patients who received endocrine therapy.